NO20024201L - Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase - Google Patents

Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase

Info

Publication number
NO20024201L
NO20024201L NO20024201A NO20024201A NO20024201L NO 20024201 L NO20024201 L NO 20024201L NO 20024201 A NO20024201 A NO 20024201A NO 20024201 A NO20024201 A NO 20024201A NO 20024201 L NO20024201 L NO 20024201L
Authority
NO
Norway
Prior art keywords
substituted
alkyl
cycloalkyl
aryl
oxdiazol
Prior art date
Application number
NO20024201A
Other languages
English (en)
Other versions
NO20024201D0 (no
NO323483B1 (no
Inventor
Karl Schoenafinger
Stefan Petry
Guenter Mueller
Karl-Heinz Baringhaus
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20024201D0 publication Critical patent/NO20024201D0/no
Publication of NO20024201L publication Critical patent/NO20024201L/no
Publication of NO323483B1 publication Critical patent/NO323483B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Det er beskrevet substituerte 3-fenyl-5-alkoksy-l,3,4-oksdiazol-2-oner med formel (1). hvori Rbetyr CC-alkyl og C-Cy-sykloalkyl; R, R, Rog R5 betyr hydrogen, halogen, nitro, C-Q-alkyl, C|-C-alkyloksy, substituert C-C-aryl-CI-C4-alkyloksy, C-C-aryloksy, C-C-aryl, C-Cx-sykloalkyl eller O-CC-sykloalkyl eller 2-oksopyrrolidin-l-yl, 2,5-dimetylpyrrol-l-yl eller NRA-R, under den forutsetning at R, R, Rog Rikke samtidig betyr hydrogen og minst én av restene R2, R3, R4 eller Rstår for resten 2-oksopyrrolidin-l-yl, 2,5-dimetylpyrrol-l-yl eller NR(-A-R, med R6 = hydrogen, C-G-alkyl eller substituert C-C,-aryl-C,-C-aIkyl, A = enkeltbinding, COn, SOn eller CONH; n = 1 eller 2; R= hydrogen, substituert C,-C|-alkyl, C:-C,- alkenyl, Cf,-C„-aryl-CC-alkyl, C-Cx-sykloalkyl-C-C-alkyl, C-Cx-sykloalkyl, C-aryl-C-Ch-alkenyl, Cf,-C-aryl, difenyl, difenyl-C|-C-alkyl, indanyl, eller gruppen Het-(CH)-, med r = 0, 1,2 eller 3 og Het = mettet eller umettet 5-7-leddet heterosyklus, som kan være benzokondensert og substituert, samt en fremgangsmåte for fremstilling av forbindelsene. Forbindelsene viser en hemmende virkning på den hormonsensitive lipasen, HSL.
NO20024201A 2000-03-07 2002-09-03 Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase samt fremgangsmate for fremstilling av forbindelsene. NO323483B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (3)

Publication Number Publication Date
NO20024201D0 NO20024201D0 (no) 2002-09-03
NO20024201L true NO20024201L (no) 2002-09-03
NO323483B1 NO323483B1 (no) 2007-05-21

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024201A NO323483B1 (no) 2000-03-07 2002-09-03 Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase samt fremgangsmate for fremstilling av forbindelsene.

Country Status (28)

Country Link
US (1) US6369088B2 (no)
EP (1) EP1263745B1 (no)
JP (1) JP2003525931A (no)
KR (1) KR100790763B1 (no)
CN (1) CN1261419C (no)
AR (1) AR027611A1 (no)
AT (1) ATE267184T1 (no)
AU (1) AU784827B2 (no)
BR (1) BR0108974A (no)
CA (1) CA2401953A1 (no)
DE (1) DE50102325D1 (no)
DK (1) DK1263745T3 (no)
EE (1) EE04877B1 (no)
ES (1) ES2218383T3 (no)
HK (1) HK1054036B (no)
HR (1) HRP20020732A2 (no)
HU (1) HUP0302772A3 (no)
IL (1) IL151518A (no)
MX (1) MXPA02008038A (no)
NO (1) NO323483B1 (no)
NZ (1) NZ521207A (no)
PL (1) PL359702A1 (no)
PT (1) PT1263745E (no)
RU (1) RU2281283C2 (no)
SK (1) SK12752002A3 (no)
TR (1) TR200401217T4 (no)
WO (1) WO2001066531A1 (no)
YU (1) YU57802A (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
WO2011108724A1 (ja) 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
AU2012352349B2 (en) 2011-12-12 2017-08-17 Receptos Llc Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
WO2016094729A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
CN113227093A (zh) 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
DE3267258D1 (en) 1981-06-15 1985-12-12 Shell Int Research 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
PT1263745E (pt) 2004-09-30
NO20024201D0 (no) 2002-09-03
MXPA02008038A (es) 2004-04-05
WO2001066531A1 (de) 2001-09-13
TR200401217T4 (tr) 2004-06-21
CN1416424A (zh) 2003-05-07
RU2281283C2 (ru) 2006-08-10
JP2003525931A (ja) 2003-09-02
AU784827B2 (en) 2006-06-29
BR0108974A (pt) 2003-06-03
ATE267184T1 (de) 2004-06-15
KR100790763B1 (ko) 2008-01-03
CN1261419C (zh) 2006-06-28
AR027611A1 (es) 2003-04-02
AU3378701A (en) 2001-09-17
EP1263745B1 (de) 2004-05-19
IL151518A0 (en) 2003-04-10
DE50102325D1 (de) 2004-06-24
US20010031772A1 (en) 2001-10-18
HUP0302772A2 (hu) 2003-11-28
SK12752002A3 (sk) 2003-04-01
PL359702A1 (en) 2004-09-06
IL151518A (en) 2008-06-05
EP1263745A1 (de) 2002-12-11
US6369088B2 (en) 2002-04-09
NZ521207A (en) 2005-04-29
KR20020079986A (ko) 2002-10-21
HK1054036A1 (en) 2003-11-14
NO323483B1 (no) 2007-05-21
WO2001066531A8 (de) 2002-07-25
ES2218383T3 (es) 2004-11-16
YU57802A (sh) 2005-07-19
HRP20020732A2 (en) 2004-12-31
EE04877B1 (et) 2007-08-15
CA2401953A1 (en) 2001-09-13
EE200200498A (et) 2004-02-16
HUP0302772A3 (en) 2007-03-28
HK1054036B (zh) 2006-11-17
DK1263745T3 (da) 2004-08-16

Similar Documents

Publication Publication Date Title
NO20024201L (no) Substituerte 3-fenyl-5-alkoksy-1,3,4-oksdiazol-2-on og anvendelse derav for hemning av hormonsensitiv lipase
DK117087D0 (da) Heterocycliske forbindelser, deres fremstilling oganvendelse som insekticider
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
NO20073465L (no) Benzotiazol-derivater
HUP0204418A2 (hu) NHE-1 inhibitor hatású N-[(helyettesített öttagú, di- vagy triaza-, kétszeresen telítetlen gyűrű)-karbonil]-guanidin-származékok és alkalmazásuk
ES2122504T3 (es) Ciertas pirrol-carboxanilidas condensadas; una nueva clase de ligandos del receptor cerebral de gaba.
ES2183439T3 (es) Mezclas fungicidas a base de piridinamidas y clorotalonil.
NO20006282L (no) Nye cyklosporiner
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
NO954453L (no) Nye pyridin-, pyrimidin- og benzenderivater som adreno-ceptorantagonister
NO924522L (no) Optisk aktive azolforbindelser, deres fremstilling og anvendelse
HUP0401488A2 (hu) Fungicid hatású 7-amino-triazolopirimidinek, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények
NO996108L (no) 9-oksinerytromycinderivater
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-<n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl>-chroman
MY117680A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives
NO970293L (no) Substituerte camptothecinderivater og fremgangsmåte for deres fremstilling
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
NO994900L (no) Forbindelser
NO932130L (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
MX9400566A (es) Complejo de b-aminoalcoxiborano opticamente activo.
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
TW333532B (en) Benzopyrans
NO20014234L (no) Pyrazol-3-on-derivater som faktor-Xa-inhibitorer
WO1989001473A3 (fr) Procede de production de derives de 2,5-diamino-6-nitro-pyridine, leur utilisation comme colorants de cheveux et nouveaux derives de 2,5-diamino-6-nitro-pyridine
FR2707990B1 (fr) Nouvelles nitrones utilisables pour le piégeage des radicaux libres.